These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 19889218)
1. Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro. Aljofan M; Sganga ML; Lo MK; Rootes CL; Porotto M; Meyer AG; Saubern S; Moscona A; Mungall BA Virol J; 2009 Nov; 6():187. PubMed ID: 19889218 [TBL] [Abstract][Full Text] [Related]
2. Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening. Aljofan M; Saubern S; Meyer AG; Marsh G; Meers J; Mungall BA Virus Res; 2009 Jun; 142(1-2):92-9. PubMed ID: 19428741 [TBL] [Abstract][Full Text] [Related]
3. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. Elshabrawy HA; Fan J; Haddad CS; Ratia K; Broder CC; Caffrey M; Prabhakar BS J Virol; 2014 Apr; 88(8):4353-65. PubMed ID: 24501399 [TBL] [Abstract][Full Text] [Related]
4. Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. Aljofan M; Porotto M; Moscona A; Mungall BA J Virol Methods; 2008 Apr; 149(1):12-9. PubMed ID: 18313148 [TBL] [Abstract][Full Text] [Related]
5. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. Porotto M; Orefice G; Yokoyama CC; Mungall BA; Realubit R; Sganga ML; Aljofan M; Whitt M; Glickman F; Moscona A J Virol; 2009 May; 83(10):5148-55. PubMed ID: 19264786 [TBL] [Abstract][Full Text] [Related]
6. Detailed Molecular Biochemistry for Novel Therapeutic Design Against Nipah and Hendra Virus: A Systematic Review. Bhattacharya S; Dhar S; Banerjee A; Ray S Curr Mol Pharmacol; 2020; 13(2):108-125. PubMed ID: 31657692 [TBL] [Abstract][Full Text] [Related]
7. Developments towards effective treatments for Nipah and Hendra virus infection. Bossart KN; Broder CC Expert Rev Anti Infect Ther; 2006 Feb; 4(1):43-55. PubMed ID: 16441208 [TBL] [Abstract][Full Text] [Related]
8. Activity of gentian violet and brilliant green against some microorganisms associated with skin infections. Bakker P; Van Doorne H; Gooskens V; Wieringa NF Int J Dermatol; 1992 Mar; 31(3):210-3. PubMed ID: 1568820 [TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. Porotto M; Carta P; Deng Y; Kellogg GE; Whitt M; Lu M; Mungall BA; Moscona A J Virol; 2007 Oct; 81(19):10567-74. PubMed ID: 17652384 [TBL] [Abstract][Full Text] [Related]
10. Containing the contagion: treating the virus that inspired the film. Lee B Sci Transl Med; 2011 Oct; 3(105):105fs6. PubMed ID: 22013121 [TBL] [Abstract][Full Text] [Related]
11. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections. Dang HV; Chan YP; Park YJ; Snijder J; Da Silva SC; Vu B; Yan L; Feng YR; Rockx B; Geisbert TW; Mire CE; Broder CC; Veesler D Nat Struct Mol Biol; 2019 Oct; 26(10):980-987. PubMed ID: 31570878 [TBL] [Abstract][Full Text] [Related]
12. Viral entry inhibitors targeted to the membrane site of action. Porotto M; Yokoyama CC; Palermo LM; Mungall B; Aljofan M; Cortese R; Pessi A; Moscona A J Virol; 2010 Jul; 84(13):6760-8. PubMed ID: 20357085 [TBL] [Abstract][Full Text] [Related]
13. A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus. Tigabu B; Rasmussen L; White EL; Tower N; Saeed M; Bukreyev A; Rockx B; LeDuc JW; Noah JW Assay Drug Dev Technol; 2014 Apr; 12(3):155-61. PubMed ID: 24735442 [TBL] [Abstract][Full Text] [Related]